Group | Compound assessed | Dose | Tmax | Cmax | AUC0-t | AUC0-inf | t1/2 |
---|---|---|---|---|---|---|---|
µmol/kg | h | µmol/l | µmol ⋅ l−1 ⋅ h | h | |||
MIV-247 | MIV-247 | 100 | 0.50 ± 0.0 | 8.7 ± 2.9 | 12 ± 3.7 | 13 ± 3.7 | 2.4 ± 0.2 |
MIV-247 and pregabalin | MIV-247 | 100 and 75 | 0.42 ± 0.1 | 11 ± 4.9 | 11 ± 5.2 | 12 ± 6.3 | 2.5 ± 1.3 |
Pregabalin | Pregabalin | 75 | 0.25 ± 0.0 | 37 ± 7.9 | 92 ± 15 | 93 ± 15 | 1.1 ± 0.1 |
MIV-247 and pregabalin | Pregabalin | 100 and 75 | 0.58 ± 0.4 | 47 ± 10 | 86 ± 16 | 87 ± 14 | 1.7 ± 0.9 |
MIV-247 | MIV-247 | 100 | 0.42 ± 0.1 | 7.5 ± 0.1 | 9.4 ± 3.0 | 11 ± 0.4 | 2.0 ± 0.8 |
MIV-247 and gabapentin | MIV-247 | 100 and 146 | 0.67 ± 0.3 | 6.5 ± 0.3 | 8.8 ± 2.2 | 9.2 ± 2.4 | 1.7 ± 0.2 |
Gabapentin | Gabapentin | 146 | 0.51 ± 0.0 | 29 ± 4.6 | 68 ± 7.3 | 69 ± 7.6 | 1.2 ± 0.2 |
MIV-247 and gabapentin | Gabapentin | 100 and 146 | 0.58 ± 0.4 | 28 ± 6.9 | 69 ± 8.2 | 72 ± 7.8 | 1.6 ± 0.3 |
Data are reported as the mean ± S.D., n = 3 per group. Data are from noninjured mice used for PK.